SERUM ALBUMIN PREDICTS ONCOLOGICAL OUTCOMES BUT NOT RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FOLLOWING PD-1 INHIBITOR THERAPY

Abstract

Background Rheumatic immune-related adverse events (irAEs) following immune checkpoint inhibitor (ICI) therapy for cancer are an increasing burden on rheumatological services but have also been associated with subsequent good oncological outcomes(1). A clinical need for biomarkers to predict rheumatic irAEs exists. High serum albumin and low lactate dehydrogenase (LDH)(2) prior to ICI therapy has been associated with subsequent good oncological outcomes, and may therefore predict rheumatic irAEs, but to the best of our knowledge this has not previously been examined. Objectives To determine the relationship between serum albumin and LDH of immune-related adverse events (irAEs) and oncologica..